Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jul-Aug;19(4):14791641221113781.
doi: 10.1177/14791641221113781.

Cardiovascular risk factors, exercise capacity and health literacy in patients with chronic ischaemic heart disease and type 2 diabetes mellitus in Germany: Baseline characteristics of the Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes study

Sophia Mt Dinges  1   2 , Janosch Krotz  3 , Felix Gass  1   2 , Julian Treitschke  1 , Isabel Fegers-Wustrow  1   2 , Marisa Geisberger  1 , Katrin Esefeld  1   2 , Pia von Korn  1   2 , André Duvinage  1   2 , Frank Edelmann  4   5 , Oliver Wolfram  6 , Julia Brandts  7 , Ephraim B Winzer  8 , Bernd Wolfarth  9 , Felix Freigang  3 , Sarah Neubauer  10 , Thomas Nebling  10 , Björn Hackenberg  11 , Volker Amelung  3 , Stephan Mueller  1   2 , Martin Halle  1   2
Affiliations
Clinical Trial

Cardiovascular risk factors, exercise capacity and health literacy in patients with chronic ischaemic heart disease and type 2 diabetes mellitus in Germany: Baseline characteristics of the Lifestyle Intervention in Chronic Ischaemic Heart Disease and Type 2 Diabetes study

Sophia Mt Dinges et al. Diab Vasc Dis Res. 2022 Jul-Aug.

Abstract

Background: Lifestyle interventions are a cornerstone in the treatment of chronic ischaemic heart disease (CIHD) and type 2 diabetes mellitus (T2DM). This study aimed at identifying differences in clinical characteristics between categories of the common lifestyle intervention targets BMI, exercise capacity (peak V̇O2) and health literacy (HL).

Methods: Cross-sectional baseline characteristics of patients enrolled in the LeIKD trial (Clinicaltrials.gov NCT03835923) are presented in total, grouped by BMI, %-predicted peak V̇O2 and HL (HLS-EU-Q16), and compared to other clinical trials with similar populations.

Results: Among 499 patients (68.3±7.7 years; 16.2% female; HbA1c, 6.9±0.9%), baseline characteristics were similar to other trials and revealed insufficient treatment of several risk factors (LDL-C 92±34 mg/dl; BMI, 30.1±4.8 kg/m2; 69.6% with peak V̇O2<90% predicted). Patients with lower peak V̇O2 showed significantly higher (p < 0.05) CIHD and T2DM disease severity (HbA1c, CIHD symptoms, coronary artery bypass graft). Obese patients had a significantly higher prevalence of hypertension and higher triglyceride levels, whereas in patients with low HL both quality of life components (physical, mental) were significantly reduced.

Conclusions: In patients with CIHD and T2DM, peak V̇O2, BMI and HL are important indicators of disease severity, risk factor burden and quality of life, which reinforces the relevance of lifestyle interventions.

Keywords: Lifestyle; cardiorespiratory fitness; chronic coronary syndrome; disease management; exercise capacity; secondary prevention.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: FE reported receiving grants from DFG, BMBF, Servier, and personal fees from Bayer Healthcare, Merck, Novartis, Servier, Berlin Chemie, Boehringer Ingelheim, Vifor Pharma, AstraZeneca and PharmaCosmos outside the submitted work. JB reported grants from AstraZeneca and personal fees from Amgen outside the submitted work. EBW reported receiving personal fees from Novartis (honoraria for lectures and advisory board activities), Boehringer Ingelheim (honoraria for advisory board activities) and CVRX (honoraria for lectures) outside the submitted work. BH reported receiving personal fees from IDS Diagnostic Systems outside the submitted work. MH reported receiving institutional funding from Techniker Krankenkasse (Health Insurance Company, Hamburg, Germany), grants from Novartis (principal investigator of the Activity Study in HFrEF) and personal fees from Bristol-Myers Squibb, Berlin Chemie-Menarini, Novartis, Daiichi-Sankyo, AstraZeneca, Roche, Abbott (advisory board on exercise and diabetes), Sanofi, Pfizer, Boehringer Ingelheim and Bayer, and serves as an advisor for Medical Park SE, Germany, outside the submitted work. All other authors (SMTD, JK, FG, JT, IFW, MG, KE, PvK, AD, OW, BW, FF, SN, TN, VA, SM) reported no conflict of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Patient recruitment in the LeIKD study. Abbreviations: CIHD, chronic ischaemic heart disease; T2DM, type 2 diabetes mellitus; aincluding re-screenings (initial screening failures may have been included during re-screening, n = 34).
See this image and copyright information in PMC

References

    1. Global Health Estimates . 2020: deaths by cause, age, sex, by Country and by Region, 2000-2019. Geneva: World Health Organization, 2020.
    1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255–323. DOI: 10.1093/eurheartj/ehz486. - DOI - PubMed
    1. Ferrannini G, Norhammar A, Gyberg V, et al. Is coronary artery disease inevitable in type 2 diabetes? From a glucocentric to a holistic view on patient management. Diabetes Care 2020; 43: 2001–2009. DOI: 10.2337/dci20-0002. - DOI - PubMed
    1. Herrington W, Lacey B, Sherliker P, et al. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016; 118: 535–546. DOI: 10.1161/circresaha.115.307611. - DOI - PubMed
    1. Ferrannini G, de Bacquer D, De Backer G, et al. Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—A persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V. Diabetes Care 2020: 43: 733. DOI: 10.2337/dc19-2165. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data